NY-DILIGENT
15.2.2024 14:01:32 CET | Business Wire | Press release
In 2023, 982 companies were subject to activist campaigns globally, a 4.6% rise compared to a year prior and the highest level since 2019. This is according to the new Diligent Market Intelligence: Shareholder Activism Annual Review 2024 report from Diligent. The findings were released live today at Diligent’s first annual Proxy Season Preview, a leading proxy season conference featuring panels and keynote speeches from the world’s most prominent stewardship specialists on topics including shareholder activism, environmental, social and governance (ESG), executive compensation and more.
According to the report, more companies are identifying activism as a risk in their corporate disclosures. In 2023, 23.4% of Russell 3000 companies disclosed shareholder activism as a risk in their 10-K reporting, up from 21.4% a year prior. Financial resilience and the introduction of the universal proxy card are driving both traditional and nontraditional activists to launch campaigns aimed at remuneration and ESG oversight.
“Market conditions are playing a notable role in shaping activist demands and the companies which activists choose to target,” said Josh Black, editor-in-chief of Diligent Market Intelligence, at Diligent. “Now more than ever, boards need to demonstrate that they are financially resilient and have strong governance practices in place to stay one step ahead.”
Three themes emerge from the report’s key findings that both boards and investors should have on their radar. These include:
Activism goes global as shareholders look to maximize returns:
- In 2023, 550 U.S. companies were publicly subjected to activist demands, a 7.8% rise compared to a year prior, with many campaigns taking aim at costly M&A transactions. The U.S. saw a 20.8% increase in the number of companies subjected to oppose M&A demands, from 24 to 29.
- 220 Asia-based companies were subject to demands in 2023, marking the third consecutive year of increasing campaigns in the region while, in Canada, 69 companies were subjected to demands a 25.5% increase compared to 2022.
- Meanwhile, shareholder activism stagnated in Europe, with 123 European companies publicly subjected to campaigns in 2023, down from a high of 177 in 2021. However, the number of board seats activists secured held steady at 36 in 2023 compared to 38 in 2022, indicating that activists are continuing to push for board representation in Europe.
Market volatility prompts increase in remuneration demands:
- Investors enhanced their focus on remuneration in 2023, keen to ensure companies have robust policies and practices in place to weather market risks. In the U.S., 81 companies faced remuneration-related demands, a 37.3% increase compared to the 59 seen in 2022 and the highest increase of any demand type.
- Shareholder proposals concerning pay are also winning increased backing. Three proposals seeking clawback policy amendments won 36.5% average support at U.S.-based companies, up from five winning 27.5% support a year prior.
Universal proxy provides an avenue for non-traditional activists to launch ESG campaigns:
- The number of ESG demands publicly made by primary- and partial-focus activists increased in 2023 to 132 demands globally, up from 114 demands a year prior, and almost double the 79 seen in 2021.
- In the U.S., the newfound freedom universal proxy offers when casting votes is bringing forth non-traditional activists, seeking board composition changes to remedy ESG shortcomings.
To download the full report, produced in association with Olshan Frome Wolosky, click here.
About the report
Data from Diligent Market Intelligence’s Activism, Voting and Shorts modules run from January 1, 2023, to December 31, 2023. Further data is available on request, although bespoke analysis may take 48 hours. For more information, please email dmi.press@diligent.com
About Diligent Market Intelligence
Diligent Market Intelligence (DMI) is a market-leading provider of shareholder activism, investor voting, and corporate governance data. Through its web application and data feeds, clients can access the most complete solution for listed company intelligence on the market, with broader and deeper insights than ever before.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215609851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
